---
layout: default
title: Abies Balsamea Leaf Oil Alnus Rhombifolia Bark Ama
parent: 僅模型預測 (L5)
nav_order: 47
evidence_level: L5
indication_count: 0
---

# Abies Balsamea Leaf Oil Alnus Rhombifolia Bark Ama
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Allergen Extract Complex: Insufficient Data for TxGNN Repurposing Evaluation

## One-Sentence Summary

This entry represents a 24-component allergen extract mixture — including tree and grass pollens, plant materials, animal tissue extracts, corticotropin, and histamine dihydrochloride — with no approved indications in Taiwan and no DrugBank identifier.
The TxGNN model was unable to generate any repurposing predictions, likely because a 24-ingredient complex cannot be mapped as a single node in the drug–disease knowledge graph.
As a result, **no evidence supports a repurposing direction at this time**, and the pipeline cannot proceed without fundamental data remediation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN produced no output) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; in this case, no prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

TxGNN operates by mapping a drug's DrugBank ID to a node in a biomedical knowledge graph, then scoring candidate disease associations via graph neural network propagation.
This evaluation failed at the very first step: the submission contains **24 distinct active ingredients** (pollens, plant extracts, animal-derived materials, corticotropin, histamine, and tabtoxin), with no single DrugBank ID assigned to the complex as a whole.
Without a resolvable entity in the knowledge graph, the model has no starting node from which to propagate predictions.

From a pharmacological standpoint, the mixture appears to be formulated as an **allergen immunotherapy or allergy-testing product**, given the co-presence of multiple aeroallergen extracts (tree pollens: birch, pine, juniper, cottonwood, cypress, alder; grass pollens: fescue, bluegrass, rye; weed pollens: lamb's quarters, ribwort plantain, cocklebur, amaranth), histamine dihydrochloride (a standard positive control for allergy skin tests), and sodium chloride as diluent.
The inclusion of corticotropin (ACTH) and Sus scrofa adrenal gland extract introduces additional hormonal components whose role in the mixture is unclear without a package insert.

Because the product is a heterogeneous biological mixture rather than a chemically defined single entity, standard drug repurposing methodology — including TxGNN — is not directly applicable without substantial reformulation of the research question.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline cannot generate a repurposing prediction for a 24-ingredient complex with no DrugBank ID, no approved indications, and no resolvable knowledge-graph entity. There is no actionable evidence to support advancing this candidate.

**To proceed, the following is needed:**

- **Identify the intended product type**: Confirm whether this is an allergen immunotherapy product, an allergy diagnostic reagent, or another formulation category. Each requires a fundamentally different evaluation pathway.
- **Decompose into individual active ingredients**: If the goal is repurposing evaluation, select one pharmacologically distinct component (e.g., corticotropin, which has its own DrugBank entry and established MOA) and submit it as a standalone query.
- **Obtain a DrugBank ID or UNII for the complex**: If the product is registered under a single identifier elsewhere (e.g., FDA UNII or NDA number), that identifier may allow knowledge-graph mapping.
- **Source the package insert**: Retrieve the full prescribing information from TFDA or the originating regulatory authority to clarify approved indications, contraindications, and warnings — currently all blocking data gaps (DG001, DG002).
- **Reassess pipeline eligibility**: Standard drug repurposing methodology applies to single-entity small molecules or biologics. A multi-allergen mixture may require a separate evidence synthesis approach (e.g., systematic review of allergen immunotherapy outcomes) rather than graph-based model inference.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

